CircRNA_0044556 affects the sensitivity of triple-negative breast cancer cells to paclitaxel by regulating miR-665

References

• Lemesle M, Geoffroy M, Alpy F, et al. CLDN1 sensitizes triple-negative breast cancer cells to chemotherapy. Cancers. 2022;14(20):5026. doi: 10.3390/cancers14205026.
   PubMed Web of Science ®Google Scholar
• Shen L, O'Shea JM, Kaadige MR, et al. Metabolic reprogramming in triple-negative breast cancer through myc suppression of TXNIP. Proc Natl Acad Sci U S A. 2015;112(17):5425–5430. doi: 10.1073/pnas.1501555112.
   PubMed Web of Science ®Google Scholar
• Green-Tripp G, Nattress C, Halldén G. Targeting triple negative breast cancer with oncolytic adenoviruses. Front Mol Biosci. 2022;9:901392. doi: 10.3389/fmolb.2022.901392.
   PubMed Web of Science ®Google Scholar
• Ferrari P. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci. 2022;23(3):1665.
   PubMed Web of Science ®Google Scholar
• Asano T. Drug resistance in cancer therapy and the role of epigenetics. J Nippon Med Sch. 2020;87(5):244–251. doi: 10.1272/jnms.JNMS.2020_87-508.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Hansen TB, Venø MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–565. doi: 10.1038/onc.2017.361.
   PubMed Web of Science ®Google Scholar
• Zhao ZJ, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. RNA Biol. 2017;14(5):514–521. doi: 10.1080/15476286.2015.1122162.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F. Triple-negative breast cancer: identification of circRNAs with efficacy in preclinical in vivo models. Cancer Genomics Proteomics. 2023;20(2):117–131. doi: 10.21873/cgp.20368.
   PubMed Web of Science ®Google Scholar
• Zheng S-R, Huang Q-D, Zheng Z-H, et al. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway. J Biochem. 2021;169(5):601–611. doi: 10.1093/jb/mvaa148.
   PubMed Web of Science ®Google Scholar
• Li H, Xu W, Xia Z, et al. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/akt/mTOR signaling. Aging. 2021;13(3):4522–4551. doi: 10.18632/aging.202415.
   PubMedGoogle Scholar
• Chen J, Shi P, Zhang J, et al. CircRNA_0044556 diminishes the sensitivity of triple‑negative breast cancer cells to adriamycin by sponging miR‑145 and regulating NRAS. Mol Med Rep. 2022;25(2):1–12. doi: 10.3892/mmr.2021.12567.
   PubMed Web of Science ®Google Scholar
• Afzal S, Hassan M, Ullah S, et al. Breast cancer; discovery of novel diagnostic biomarkers, drug resistance, and therapeutic implications. Front Mol Biosci. 2022;9:783450. doi: 10.3389/fmolb.2022.783450.
   PubMed Web of Science ®Google Scholar
• Ding L, Gu H, Xiong X, et al. MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance and applications in human triple-negative breast cancer. Cells. 2019;8(12):1492. doi: 10.3390/cells8121492.
   PubMed Web of Science ®Google Scholar
• Li J, Lu M, Jin J, et al. miR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22. Cell Physiol Biochem. 2018;50(1):136–149. doi: 10.1159/000493964.
   PubMedGoogle Scholar
• Zhao X-G, Hu J-Y, Tang J, et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 2019;10(7):479. doi: 10.1038/s41419-019-1705-z.
   PubMedGoogle Scholar
• Ma X, Deng C. Circ_0044556 promotes the progression of colorectal cancer via the miR-665-Dependent expression regulation of diaphanous homolog 1. Dig Dis Sci. 2022;67(9):4458–4470. doi: 10.1007/s10620-021-07310-w.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhu W, Xu A, et al. Inhibition of FOXO1‑mediated autophagy promotes paclitaxel‑induced apoptosis of MDA‑MB‑231 cells. Mol Med Rep. 2022;25(2):1–11. doi: 10.3892/mmr.2022.12588.
   PubMed Web of Science ®Google Scholar
• Yen W-C, Corpuz MR, Prudente RY, et al. A selective retinoid X receptor agonist bexarotene (targretin) prevents and overcomes acquired paclitaxel (taxol) resistance in human non-small cell lung cancer. Clin Cancer Res. 2004;10(24):8656–8664. doi: 10.1158/1078-0432.CCR-04-0979.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Yang J, et al. Circ-TRIO promotes TNBC progression by regulating the miR-432-5p/CCDC58 axis. Cell Death Dis. 2022;13(9):776. doi: 10.1038/s41419-022-05216-7.
   PubMed Web of Science ®Google Scholar
• Hossain MT, Li S, Reza MS, et al. Identification of circRNA biomarker for gastric cancer through integrated analysis. Front Mol Biosci. 2022;9:857320. doi: 10.3389/fmolb.2022.857320.
   PubMed Web of Science ®Google Scholar
• Jing L, Wu J, Tang X, et al. Identification of circular RNA hsa_circ_0044556 and its effect on the progression of colorectal cancer. Cancer Cell Int. 2020;20(1):427. doi: 10.1186/s12935-020-01523-1.
   PubMed Web of Science ®Google Scholar
• Ma Y, Ren Y, Wen H, et al. circCOL1A1 promotes the progression of gastric cancer cells through sponging miR-145 to enhance RABL3 expression. J Immunol Res. 2021;2021:6724854–6724820. doi: 10.1155/2021/6724854.
   PubMedGoogle Scholar
• Ye M, Song Y, Pan S, et al. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy. Pharmacol Ther. 2020;215:107633. doi: 10.1016/j.pharmthera.2020.107633.
   PubMed Web of Science ®Google Scholar
• Fu L, Huo J, Fitrat H, et al. CircNRIP1 exerts oncogenic functions in papillary thyroid carcinoma by sponging miR-653-5p and regulating PBX3 expression. J Oncol. 2022;2022:2081501–2081512. doi: 10.1155/2022/2081501.
   PubMed Web of Science ®Google Scholar
• Yin Y, Long J, He Q, et al. Emerging roles of circRNA in formation and progression of cancer. J Cancer. 2019;10(21):5015–5021. doi: 10.7150/jca.30828.
   PubMed Web of Science ®Google Scholar
• Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24(16):R762–76. doi: 10.1016/j.cub.2014.06.043.
   PubMed Web of Science ®Google Scholar
• Wang W, Ying Y, Xie H, et al. miR-665 inhibits epithelial-to-mesenchymal transition in bladder cancer via the SMAD3/SNAIL axis. Cell Cycle. 2021;20(13):1242–1252. doi: 10.1080/15384101.2021.1929677.
   PubMed Web of Science ®Google Scholar
• Bai N, Peng E, Xia F, et al. CircABCC2 regulates hepatocellular cancer progression by decoying MiR-665. J Cancer. 2019;10(17):3893–3898. doi: 10.7150/jca.31362.
   PubMed Web of Science ®Google Scholar
• Wu K-Z, Zhang C-D, Zhang C, et al. miR-665 suppresses the Epithelial-Mesenchymal transition and progression of gastric cancer by targeting CRIM1. Cancer Manag Res. 2020;12:3489–3501. doi: 10.2147/CMAR.S241795.
   PubMed Web of Science ®Google Scholar
• Zhou P, Xiong T, Yao L, et al. MicroRNA-665 promotes the proliferation of ovarian cancer cells by targeting SRCIN1. Exp Ther Med. 2020;19(2):1112–1120. doi: 10.3892/etm.2019.8293.
   PubMed Web of Science ®Google Scholar
• Dong M, Li P, Xie Y, et al. CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR. Drug Dev Res. 2021;82(8):1193–1205. doi: 10.1002/ddr.21834.
   PubMed Web of Science ®Google Scholar